Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs

Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma Paris and Tarrytown, N.Y. – January 8, 2018 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will accelerate and expand investment for the clinical development of the PD-1 (programmed cell death protein 1) antibody cemiplimab in oncology and dupilumab in Type 2 allergic diseases. […]